ArticleEuropean radiology2016
The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.
Article in European radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Comparison of diffusion-weighted imaging and MR elastography in staging liver fibrosis: a meta-analysis.Abdominal radiology (New York) · 2021Pooled it
- Pooled it
- Can quantified diffusion-weighted imaging predict histopathological features of liver tumors?European radiology · 2023Article
- Correction to: Comparison of diffusion‑weighted imaging and MR elastography in staging liver fibrosis: a meta‑analysis.Abdominal radiology (New York) · 2023Article
- Imaging Phenotypes and Evolution of Hepatic Langerhans Cell Histiocytosis on CT/MRI: A Retrospective Study of Clinical Cases and Literature Review.Bioengineering (Basel, Switzerland) · 2023Article
- Multiparametric MRI combined with liver volume for quantitative evaluation of liver function in patients with cirrhosis.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Magnetic Resonance Imaging of Liver Fibrosis, Fat, and Iron.Radiologic clinics of North America · 2022Review
- Quantitative diffusion MRI of the abdomen and pelvis.Medical physics · 2022Article
- Fat- and iron-corrected ADC to assess liver fibrosis in patients with chronic hepatitis B.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Consensus report from the 9European radiology · 2021Review
- Assessment of Liver Fibrosis Stage Using Integrative Analysis of Hepatic Heterogeneity and Nodularity in Routine MRI with FIB-4 Index as Reference Standard.Journal of clinical medicine · 2021Article
- Association between liver diffusion-weighted imaging apparent diffusion coefficient values and other measures of liver disease in pediatric autoimmune liver disease patients.Abdominal radiology (New York) · 2021Article
- Quantification of liver function using gadoxetic acid-enhanced MRI.Abdominal radiology (New York) · 2020Review
- Imaging biomarkers of diffuse liver disease: current status.Abdominal radiology (New York) · 2020Article
- Advances in functional and molecular MRI technologies in chronic liver diseases.Journal of hepatology · 2020Review
- Introduction to Quantitative Susceptibility Mapping and Susceptibility Weighted Imaging.The British journal of radiology · 2019Review
- Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis.European radiology · 2019Article
- High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis.Annals of translational medicine · 2019Article
- Imaging of Hepatic Fibrosis.Current gastroenterology reports · 2018Review
- Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.Abdominal radiology (New York) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the diagnostic efficacy of multiparametric MRI using quantitative measurements of the apparent diffusion coefficient (ADC) of the liver parenchyma on diffusion-weighted imaging (DWI), signal intensity (SI) on susceptibility-weighted imaging (SWI), and gadoxetic acid-enhanced T1-weighted imaging during the hepatobiliary phase for the staging of liver fibrosis. MATERIALS AND
methodsSeventy-seven patients underwent a 3T MRI examination, including DWI/SWI sequences and gadoxetic acid-enhanced T1-weighted MRI. Liver fibrosis according to liver biopsy was staged using the Metavir fibrosis score: F0 (n = 21, 27.3%); F1 (n = 7, 9.1%); F2 (n = 8, 10.4%); F3 (n = 12, 15.6%); and F4 (n = 29, 37.7%). SI of the liver was defined using region-of-interest measurements to calculate the ADC values, the relative enhancement (RE) in the hepatobiliary phase, and the liver-to-muscle ratio (LMR) measurements for SWI.
resultsThe values of RE, LMR, and ADC measurements were statistically significantly different among the five fibrosis stages (p < 0.004). Combining the three parameters in a multiparametric approach, the AUC for detecting F1 stage or greater (≥ F1) was 94%, for F2 or greater (≥F2) was 95%, for F3 or greater (≥F3) was 90%, and for stage F4 was 93%.
conclusionsMultiparametric MRI is an efficient non-invasive diagnostic tool for the staging of liver fibrosis. KEY POINTS: • Multiparametric MRI has high accuracy in predicting moderate or greater liver fibrosis. • Relative enhancement post- gadoxetic acid is an independent predictor of liver fibrosis. • Liver SWI signal intensity and ADC values enhance the diagnostic ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.